About the Infectious Disease Treatment Market in China
Infectious diseases are caused by pathogenic microorganisms such as bacteria, parasites, fungi, or viruses. They can be transmitted from one person to another through direct or indirect contact. Anti-infective drugs are used to kill (cidal) or stop the growth (static) of infectious agents. Based on target organism, anti-infective drugs can be categorized into antibacterial, antifungal, antiviral, and antiparasitic.
Technavio’s analysts forecast the infectious disease treatment market in China to grow at a CAGR of 5.01% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the infectious disease treatment market in China for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat infectious diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
Technavio's report, Infectious Disease Treatment Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• GSK
• Johnson & Johnson
• Merck
• Pfizer
Other prominent vendors
• Achaogen
• Actelion
• Adenovir Pharma
• AstraZeneca
• Bayer
• Biocryst
• Celsus therapeutics
• Cempra
• Eleven Biotherapeutics
• Exoxemis
• Ferrer International
• Griffin Discoveries
• Hexima
• InSite Vision
• Insmed Incorporated
• KaloBios Pharmaceuticals
• Lytix Biopharma
• Meiji Seika Pharma
• Melinta Therapeutics
• Moberg Pharma
• NanoViricides
• Nektar
• NicOx
• NovaBay
• NovaBiotics
• Ocular Therapeutix
• Panoptes Pharma
• Paratek Pharmaceuticals
• Polichem
• PTC Therapeutics
• RedHill
• Shire
• Starpharma Holdings
• Sun Pharma
• Symbiomix
• Tetraphase Pharmaceuticals
• The Medicines Company
• Theravance Biopharma
• Topica Pharmaceuticals
• Vertex Pharmaceuticals
• Viamet Pharmaceuticals
Market driver
• Use of combination therapies
• For a full, detailed list, view our report
Market challenge
• Development of drug resistant strains
• For a full, detailed list, view our report
Market trend
• Emergence of interferon (IFN)-free therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Assumptions
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: China - An overview
Social and economic conditions
Healthcare reforms
Healthcare infrastructure
PART 06: Opportunities for global and local vendors
Local vendors
Global vendors
PART 07: Pipeline analysis
AC-170
DEXTENZA
Zerbaxa
Surotomycin
MK-3415A
Amikacin Inhale
CARBAVANCE
Eravacycline
Plazomicin
Delafloxacin
Solithromycin
VivaGel
Arikayce
Cadazolid
Ozenoxacin
TDT 067
MOB-015
1334H
Auriclosene
EBI-005
FST-100
VT-1161
Luliconazole solution, 10%
ME1111
NP213
HXP124
SPL7013
OPX-1
AzaSite Xtra (ISV-405)
GD134
PART 08: Market landscape
Pharmaceutical market in China
Market overview
Market size and forecast
Five forces analysis
PART 09: Market segmentation by application
PART 10: Antibacterial drugs market in China
MOA
Market size and forecast
PART 11: Antiviral drugs market in China
Market size and forecast
Market segmentation by disease
Hepatitis C drugs market in China
Hepatitis B drugs market in China
HIV drugs market in China
PART 12: Antifungal drugs market in China
Market size and forecast
PART 13: Antiparasitic drugs market in China
PART 14: Market drivers
Climatic changes
Increased exposure to chemicals and pollutants
Use of combination therapies
Increased prevalence of infectious diseases
Increase in awareness
PART 15: Impact of drivers
PART 16: Market challenges
Counterfeit drugs
Development of drug-resistant strains
Patent expiries and generic penetration
Decreased investments in research
Increased use of generics and CAMs
PART 17: Impact of drivers and challenges
PART 18: Market trends
Increase in collaborations and M&A
Emergence of IFN-free therapies
Increase in injection drug users
PART 19: Vendor landscape
Competitive scenario
F. Hoffmann-La Roche
Gilead Sciences
GSK
Johnson & Johnson
Merck
Pfizer
Other prominent vendors
PART 20: Appendix
List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: China GDP 2010-2014 ($ trillions)
Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 04: Healthcare reforms in China
Exhibit 05: New drug approval (NDA) review process in China
Exhibit 06: New drug approval process in China
Exhibit 07: Drug registration classification and requirements in China
Exhibit 08: Infectious diseases treatment market in China: Pipeline portfolio
Exhibit 09: Pharmaceutical market in China 2015-2020 ($ billions)
Exhibit 10: China pharmaceutical market overview: SWOT analysis
Exhibit 11: Share of infectious diseases market in pharmaceutical market in China 2015
Exhibit 12: Infectious disease treatment market in China 2015-2020 ($ billions)
Exhibit 13: Venues for purchasing anti-infective drugs in China
Exhibit 14: Five forces analysis
Exhibit 15: Infectious disease treatment market in China segmentation by application
Exhibit 16: Infectious disease treatment market in China segmentation by application 2015
Exhibit 17: Infectious disease treatment market in China segmentation by application 2020
Exhibit 18: Infectious disease treatment market in China segmentation by application 2015-2020 ($ billions)
Exhibit 19: Infectious disease treatment market in China segmentation by application 2015-2020 (percentage)
Exhibit 20: Infectious disease treatment market in China 2015-2020
Exhibit 21: YoY growth rate of Infectious disease treatment market in China segments 2015-2020
Exhibit 22: MOA of antibacterial drugs
Exhibit 23: Antibacterial drugs market in China 2015-2020 ($ billions)
Exhibit 24: Segmentation of antibacterial drugs market by chemical class
Exhibit 25: Cephalosporin segmentation by generation of drugs
Exhibit 26: Antibacterial drugs market in China revenue segmentation by chemical class
Exhibit 27: Segmentation of antibacterial drugs market in China by drug origin
Exhibit 28: Antiviral drugs market in China 2015-2020 ($ billions)
Exhibit 29: Segmentation of antiviral drugs market in China by disease 2015
Exhibit 30: Segmentation of antiviral drugs market in China by disease 2020
Exhibit 31: Hepatitis C drugs market in China ($ billions)
Exhibit 32: Hepatitis B drugs market in China 2015-2020 ($ millions)
Exhibit 33: Segmentation of hepatitis B and C market based on MOA
Exhibit 34: HIV drugs market in China ($ millions)
Exhibit 35: HIV drugs market segmentation by drug class 2015
Exhibit 36: Antifungal drugs market in China 2015-2020 ($ millions)
Exhibit 37: Antifungal drugs market in China segmentation by chemical class
Exhibit 38: Antifungal drugs market segmentation by chemical class 2015
Exhibit 39: Antiparasitic drugs market in China ($ millions)
Exhibit 40: Impact of drivers
Exhibit 41: Antibiotic-resistant strains according to the period of development of resistance
Exhibit 42: Impact of drivers and challenges
Exhibit 43: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Pegasys (international) 2013-2015 ($ millions)
Exhibit 44: F. Hoffmann-La F. Hoffmann-La Roche: YoY revenue and growth rate of Tamiflu (international) 2013-2015 ($ millions)
Exhibit 45: F. Hoffmann-La F. Hoffmann-La Roche: Key takeaways
Exhibit 46: Gilead Sciences: YoY revenue and growth rate of Truvada (international markets) 2013-2015 ($ millions)
Exhibit 47: Gilead Sciences: YoY revenue and growth rate of Atripla (international markets) 2013-2015 ($ millions)
Exhibit 48: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
Exhibit 49: Gilead Sciences: YoY revenue and growth rate of Complera (international markets) 2013-2015 ($ millions)
Exhibit 50: Gilead Sciences: Key takeaways
Exhibit 51: GlaxoSmithKline: Key takeaways
Exhibit 52: Johnson & Johnson: YoY revenue and growth rate of Olysio (International markets) 2013-3015 ($ millions)
Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Prezista (international markets) 2013-3015 ($ millions)
Exhibit 54: Johnson & Johnson: YoY revenue and growth rate of Edurant (international markets) 2013-3015 ($ millions)
Exhibit 55: Johnson & Johnson: Key takeaways
Exhibit 56: Merck: YoY revenue and growth rate of Cancidas (international markets) 2013-2015 ($ millions)
Exhibit 57: Merck: YoY revenue and growth rate of Pegintron (international markets) 2013-2015 ($ millions)
Exhibit 58: Merck: YoY revenue and growth rate of Isentress (international markets) 2013-2015 ($ millions)
Exhibit 59: Merck: YoY revenue and growth rate of Invanz (international markets) 2013-2015 ($ millions)
Exhibit 60: Merck: YoY revenue and growth rate of Noxafil (international markets) 2013-2015 ($ millions)
Exhibit 61: Merck: YoY revenue of Cubicin (international markets) 2013-2015 ($ millions)
Exhibit 62: Merck: Key takeaways
Exhibit 63: Pfizer: YoY revenue and growth rate of Diflucan (emerging markets) 2013-2015 ($ millions)
Exhibit 64: Pfizer: YoY revenue and growth rate of Suplerazon (emerging markets) 2013-2015 ($ millions)
Exhibit 65: Pfizer: YoY revenue and growth rate of Tygacil (Emerging markets) 2013-2015 ($ millions)
Exhibit 66: Pfizer: YoY revenue and growth rate of Vfend (emerging markets) 2013-2015 ($ millions)
Exhibit 67: Pfizer: YoY revenue and growth rate of Zithromax (emerging markets) 2013-2015 ($ millions)
Exhibit 68: Pfizer: YoY revenue and growth rate of Zyvox (emerging markets) 2013-2015 ($ millions)
Exhibit 69: Pfizer: YoY revenue and growth rate of Tygacil (emerging markets) 2013-2015 ($ millions)
Exhibit 70: Pfizer: Key takeaways
